Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
Market Cap:419.6M; Shares Outstanding:105.2M; Short Interest: 1.46%; Q3 2019(9/30/19): Cash 103M. Loss 39.5M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
|Date||Sales||% last year||% last quarter|
Total institutions: 61，no change
Shares hold: 68108.8k shares. no change
shares% hold: 64.76%，no change